For the first time ever King's College London and a cannabis company are teaming up “because of the CBD awareness market” Geremey Thomas, CEO Sativa Investments PLC told Directors Talk. Sativa Investments is currently assisting prestigious King's College London to research cannabinoids for medicinal use.
On the back of this, Goodbody and Blunt, the retail offshoot of Sativa launched its first shop in Bath this week.
100’s of these CBD Wellness stores will be rolled out throughout the British High Street – and could prove to be an exciting distribution point for CBD products. It aims to be the country's most innovative and ambitious CBD vehicle.
What is the research for?
Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids, subject to regulatory approval.
Professor Clive Page OBE PhD Professor of Pharmacology at King's College London will lead the research. “With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King's College London will assist the medical profession, government and regulators in their deliberations,” said Sativa founder and chief executive, Geremy Thomas.
“As the UK's first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago.”
Why Sativa Investments contract with Kings College is an important step
The team aims to research the impact of cannabinoids on inflammation and respiratory diseases. Industry observers will note this is an interesting development – where a world-ranking university aligns itself with a medicinal cannabis investor. The move indicates the ethics around cannabis research is in a state of rapid change.